Theravance is a company.
Key people at Theravance.
Theravance was founded by Jim Tananbaum (Co-Founder and Chief Executive Officer).
Theravance was founded by Jim Tananbaum (Co-Founder and Chief Executive Officer).
Key people at Theravance.
Theravance Biopharma, Inc. is a biopharmaceutical company headquartered in South San Francisco, CA, focused on discovering, developing, and commercializing organ-selective medicines to transform treatments for specialty respiratory and neurologic diseases.[1][2][3] It serves patients with serious conditions like chronic obstructive pulmonary disease (COPD) and symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA), addressing unmet needs through its FDA-approved product YUPELRI® (revefenacin) for COPD maintenance and late-stage investigational drug ampreloxetine for nOH in MSA patients.[3][5] With 98 employees and $64.4M in revenue, the company reported record YUPELRI net sales and non-GAAP breakeven in Q3 2025, signaling strong growth momentum driven by financial discipline and pipeline advancement.[2][5]
Theravance Biopharma emerged from decades of expertise in biopharma innovation, evolving into a focused entity dedicated to organ-selective medicines for respiratory and neurologic conditions.[1][3] While specific founding details are not detailed in available sources, the company has developed key assets like YUPELRI®, FDA-approved for COPD, and advanced ampreloxetine through late-stage trials, marking pivotal moments in commercialization and clinical progress.[3][5] Its strategic anchors—insight-driven innovation, outsourcing non-core processes, integrated teams, and uncertainty management—have shaped its path to delivering "Medicines that Make a Difference®."[3]
Theravance rides the wave of precision medicine in biopharma, focusing on organ-selective therapies amid rising demand for targeted treatments in aging populations with chronic respiratory and neurodegenerative diseases like COPD and MSA.[1][3][5] Timing aligns with post-pandemic emphasis on respiratory health and unmet neurologic needs, bolstered by market forces such as FDA approvals and payer support for innovative inhalers and oral therapies.[3][5] By commercializing YUPELRI and advancing ampreloxetine toward potential first-in-class status, Theravance influences the ecosystem through shareholder value creation and pipeline contributions that could expand options for underserved patients.[3][5]
Topline results from the pivotal Phase 3 CYPRESS study for ampreloxetine are expected in Q1 2026, potentially unlocking a breakthrough for MSA-nOH symptoms and driving further revenue growth beyond YUPELRI's momentum.[5] Trends like AI-accelerated drug discovery and personalized neurology will shape its trajectory, amplifying its innovation edge in a competitive biopharma landscape.[3] Theravance's disciplined approach positions it to sustain breakeven profitability while expanding its transformative impact, reinforcing its mission to deliver medicines that truly matter for serious diseases.[1][5]
